Coronary Heart DiseaseNCT05848934
Research on the Relationship Between Cognitive Function Changes and Cerebrovascular Health in Patients With Coronary Heart Disease
An observational study of Coronary Heart Disease and Image, run by Nanjing University of Traditional Chinese Medicine at 1 site in China.
Trial summary
The purpose of this study is to elucidate the imaging mechanisms of cognitive function changes in patients with coronary heart disease before and after surgery or conservative treatment, and to evaluate and predict the postoperative neurological function recovery and cerebrovascular health level of patients by… Read more about this study
- Who is it for?
- Ages 40 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Coronary Heart Disease, Image
- What is being tested?
- magnetic resonance image and Neuropsychological scale
- Type of treatment
- Medical device
- How many people
- 100 participants
- Where
- 1 siteChina
- Study dates
- 1 May 2023to 31 Dec 2025
- How long will I take part?
- 1 Year
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: All of the patients of CAD（coronary heart disease ）surgical treatment group and CAD（coronary heart disease ）conservative treatment group are in-patients and out-patients in the cardiac surgery department from the research center. The subjects of healthy control group are recruited from community.
Who may be able to join
- Confirmed coronary heart disease or risk of coronary heart disease through clinical testing
- Conscious and capable of completing neuropsychological scales
Who cannot join
- Patients with other serious heart diseases (such as aortic aneurysm)
- People with uncontrolled hypertension or diabetes
- There are contraindications to MRI examination (there are metal implants in the body, such as cardiac pacemakers, metal dentures, artificial joints, non paramagnetism stents, etc.; there is claustrophobia)
- Have a history of severe stroke, epilepsy, traumatic brain injury, and transient ischemic events
- Existence of neurological and mental disorders (schizophrenia, depression, etc.), post-traumatic stress disorder, obsessive-compulsive disorder, multiple sclerosis, amyotrophic lateral sclerosis, etc
- Have a history of alcohol or drug abuse
Show all 9Show fewer
- Those with significant organ dysfunction such as lung, liver, and kidney;
- Patients with tumor, infectious diseases, blood system disease and immune system disease;
- Currently participating in other clinical studies at the same time.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluation and Prognosis of Cerebrovascular and Neurological Health Status in Patients With Coronary Heart Disease After Treatment
The purpose of this study is to elucidate the imaging mechanisms of cognitive function changes in patients with coronary heart disease before and after surgery or conservative treatment, and to evaluate and predict the postoperative neurological function recovery and cerebrovascular health level of patients by combining serum markers and patient cardiovascular health evaluation indicators.
Read the detailed description
The focus of this study is to elucidate the impact of coronary heart disease on the morphology and cognitive changes of cerebral blood vessels in patients. Record imaging data, neuropsychological cognitive scales, serum markers, adverse cardiac events, and patient evaluation indicators before and after clinical treatment and follow-up period, and explore relevant factors affecting changes in cerebrovascular morphology and cognitive function.
- Conditions
- Coronary Heart Disease, Image
- Being tested
- magnetic resonance image, Neuropsychological scale
- Keywords
- Coronary Heart Disease, MRI Imaging, Neuropsychological assessment
- Medical subject headings
- Coronary Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
magnetic resonance imageDevice
Imaging data were collected in a strong magnetic field
Neuropsychological scaleDiagnostic test
Multi dimensional neuropsychological test
| Study group | Role | What they receive |
|---|---|---|
| CAD（coronary heart disease ）surgical treatment | Not described Receives: Device: magnetic resonance image; Diagnostic Test: Neuropsychological scale | |
| CAD（coronary heart disease ）conservative treatment | Not described Receives: Device: magnetic resonance image; Diagnostic Test: Neuropsychological scale | |
| HC （Healthy controls） | Not described Receives: Device: magnetic resonance image; Diagnostic Test: Neuropsychological scale |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change of brain volume before and after treatment
The change of brain volume (mm3) are evaluated by structural 3DT1 weighted MRI. Freesurfer software is used to get the measured value of the volume.
Measured: before operation; 3-10 Days after operation; 1 month; 6-12months
Change of cerebrovascular morphology before and after treatment
The change of Cerebral vessel density, caliber and tortuosity, brain white matter hyperintensity lesion count
Measured: before operation; 3-10 Days after operation; 1 month; 6-12months
Change of brain function connectivity before and after operation
The change of brain functional connectivity intensity are evaluated by rest stage functional MRI. DPABI software based on MATLAB is used to get the measured the matrix value of functional connectivity.
Measured: before operation; 3-10 Days after operation; 1 month; 6-12months
Secondary outcomes (9)
Change of serum marker concentration before and after operation
The change of serum marker concentration is evaluated by inflammatory cytokine.
Measured: before operation; 3-10 Days after operation; 1 month; 6-12months
Change of plasma marker concentration before and after operation
The change of plasma marker concentration is evaluated by neurofilament light chain(NFL) protein extracted from plasma.
Measured: before operation; 3-10 Days after operation; 1 month; 6-12months
Change of cardiovascular risk factors before and after operation
The change of cardiovascular risk factors is evaluated by blood routine and patients' living habits
Measured: before operation; 3-10 Days after operation; 1 month; 6-12months
Change of executive functions before and after operation evaluated by Trail-Making Test Part A
The change of executive functions are first evaluated by Trail-Making Test Part A test. The minimum value is 0 , and the maximum value is 30. This test has no clear maximum and minimum values. If the test completion time exceeds 79 seconds, it means the outcome is abnormal. The higher scores mean a worse outcome.
Measured: before operation; 3-10 Days after operation; 1 month; 6-12months
Change of working memory before and after operation evaluated by Forward Digit Span
The change of working memory is first evaluated by Forward Digit Span. The minimum value is 0 , and the maximum value is not clear. The normal range of results is 7.75±1.47. The higher scores mean a better outcome.
Measured: before operation; 3-10 Days after operation; 1 month; 6-12months
Change of working memory before and after operation evaluated by Backward Digit Span
The change of working memory is second evaluated by Backward Digit Span. The minimum value is 0 , and the maximum value is not clear. The normal range of results is 5.36±1.91. The higher scores mean a better outcome.
Measured: before operation; 3-10 Days after operation; 1 month; 6-12months
Change of executive functions before and after operation evaluated by Trail-Making Test Part B
The change of executive functions are first evaluated by Trail-Making Test Part B test. The minimum value is 0 , and the maximum value is 30. This test has no clear maximum and minimum values. If the test completion time exceeds 79 seconds, it means the outcome is abnormal. The higher scores mean a worse outcome.It is a supplement to Trail-Making Test Part A, which is optional for patients who are not familiar with the English alphabetical order
Measured: before operation; 3-10 Days after operation; 1 month; 6-12months
Change of executive functions before and after operation evaluated by Digit Symbol Coding score
The change of executive functions are second evaluated by Digit Symbol Coding score. The minimum value is 0 , and the maximum value is not clear. The normal range of results is 56.53 ± 20.17. The higher scores mean a better outcome.
Measured: before operation; 3-10 Days after operation; 1 month; 6-12months
Change of episodic memory functions before and after operation evaluated by Auditory Verbal Learning test
The change of episodic memory are evaluated by Auditory Verbal Learning test(AVLT-H).
Measured: before operation; 3-10 Days after operation; 1 month; 6-12months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 May 2023
- Study start1 May 2023 (estimated)
- Primary completion31 Dec 2025 (estimated)
- Study completion31 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Coronary Heart DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
- Target duration
- 1 Year
Sponsor and investigators
- Lead sponsor
- Nanjing University of Traditional Chinese Medicine
- Sponsor type
- University, hospital or other
- Collaborators
- Xi'an Jiaotong University, Yuncheng First Hospital
- Responsible party
- Principal investigator, Qianyan Liu, Nanjing University of Traditional Chinese Medicine
- Investigators
- Nengrui Guo, Principal investigator, Yuncheng First Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05848934
- Sponsor's protocol ID
- 82071993-1
- Status last verified
- Apr 2023
- First submitted
- 28 Apr 2023
- Last updated
- 8 May 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 May 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation and Prognosis of Cerebrovascular and Neurological Health Status in Patients With Coronary Heart Disease After Treatment
- ClinicalTrials.gov ID
- NCT05848934
- Acronym / sponsor ID
- 82071993-1
- Conditions
- Coronary Heart Disease, Image
- Keywords
- Coronary Heart Disease, MRI Imaging, Neuropsychological assessment
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Nanjing University of Traditional Chinese MedicineUniversity, hospital or other
- Collaborators
- Xi'an Jiaotong University, Yuncheng First Hospital
- Study start
- 1 May 2023 (estimated)
- Primary completion
- 31 Dec 2025 (estimated)
- Study completion
- 31 Dec 2025 (estimated)
- First posted
- 8 May 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to elucidate the imaging mechanisms of cognitive function changes in patients with coronary heart disease before and after surgery or conservative treatment, and to evaluate and predict the postoperative neurological function recovery and cerebrovascular health level of patients by combining serum markers and patient cardiovascular health evaluation indicators.
Detailed description
The focus of this study is to elucidate the impact of coronary heart disease on the morphology and cognitive changes of cerebral blood vessels in patients. Record imaging data, neuropsychological cognitive scales, serum markers, adverse cardiac events, and patient evaluation indicators before and after clinical treatment and follow-up period, and explore relevant factors affecting changes in cerebrovascular morphology and cognitive function.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 1 Year
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| CAD（coronary heart disease ）surgical treatment | – | Device: magnetic resonance image, Diagnostic Test: Neuropsychological scale |
| CAD（coronary heart disease ）conservative treatment | – | Device: magnetic resonance image, Diagnostic Test: Neuropsychological scale |
| HC （Healthy controls） | – | Device: magnetic resonance image, Diagnostic Test: Neuropsychological scale |
Who may qualify
- Ages
- 40 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- All of the patients of CAD（coronary heart disease ）surgical treatment group and CAD（coronary heart disease ）conservative treatment group are in-patients and out-patients in the cardiac surgery department from the research center. The subjects of healthy control group are recruited from community.
Key inclusion criteria (2 listed)
- Confirmed coronary heart disease or risk of coronary heart disease through clinical testing
- Conscious and capable of completing neuropsychological scales
Key exclusion criteria (9 listed)
- Patients with other serious heart diseases (such as aortic aneurysm)
- People with uncontrolled hypertension or diabetes
- There are contraindications to MRI examination (there are metal implants in the body, such as cardiac pacemakers, metal dentures, artificial joints, non paramagnetism stents, etc.; there is claustrophobia)
- Have a history of severe stroke, epilepsy, traumatic brain injury, and transient ischemic events
- Existence of neurological and mental disorders (schizophrenia, depression, etc.), post-traumatic stress disorder, obsessive-compulsive disorder, multiple sclerosis, amyotrophic lateral sclerosis, etc
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| magnetic resonance imageImaging data were collected in a strong magnetic field | Device | CAD（coronary heart disease ）conservative treatment, CAD（coronary heart disease ）surgical treatment, HC （Healthy controls） |
| Neuropsychological scaleMulti dimensional neuropsychological test | Diagnostic test | CAD（coronary heart disease ）conservative treatment, CAD（coronary heart disease ）surgical treatment, HC （Healthy controls） |
Primary outcome
Change of brain volume before and after treatment
Time frame: before operation; 3-10 Days after operation; 1 month; 6-12months
The change of brain volume (mm3) are evaluated by structural 3DT1 weighted MRI. Freesurfer software is used to get the measured value of the volume.
Change of cerebrovascular morphology before and after treatment
Time frame: before operation; 3-10 Days after operation; 1 month; 6-12months
The change of Cerebral vessel density, caliber and tortuosity, brain white matter hyperintensity lesion count
Change of brain function connectivity before and after operation
Time frame: before operation; 3-10 Days after operation; 1 month; 6-12months
The change of brain functional connectivity intensity are evaluated by rest stage functional MRI. DPABI software based on MATLAB is used to get the measured the matrix value of functional connectivity.
9 secondary outcomes
Change of serum marker concentration before and after operation
Time frame: before operation; 3-10 Days after operation; 1 month; 6-12months
Change of plasma marker concentration before and after operation
Time frame: before operation; 3-10 Days after operation; 1 month; 6-12months
Change of cardiovascular risk factors before and after operation
Time frame: before operation; 3-10 Days after operation; 1 month; 6-12months
Change of executive functions before and after operation evaluated by Trail-Making Test Part A
Time frame: before operation; 3-10 Days after operation; 1 month; 6-12months
Change of working memory before and after operation evaluated by Forward Digit Span
Time frame: before operation; 3-10 Days after operation; 1 month; 6-12months
Change of working memory before and after operation evaluated by Backward Digit Span
Time frame: before operation; 3-10 Days after operation; 1 month; 6-12months
Change of executive functions before and after operation evaluated by Trail-Making Test Part B
Time frame: before operation; 3-10 Days after operation; 1 month; 6-12months
Change of executive functions before and after operation evaluated by Digit Symbol Coding score
Time frame: before operation; 3-10 Days after operation; 1 month; 6-12months
Change of episodic memory functions before and after operation evaluated by Auditory Verbal Learning test
Time frame: before operation; 3-10 Days after operation; 1 month; 6-12months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 May 2023.
Related trials for Coronary Heart Disease
Enrolling by invitationObservational study
Multi-Scale Analysis of Phenotypes in Heart Failure (MAP-HEART)
Heart Failure
Not yet recruiting
Effects of Adding Vagal Neuromodulation to Manual Therapy in Women With Fibromyalgia
Fibromyalgia (FM) OR Fibromyalgia Syndrome, Manuel Therapy
Active, not recruitingObservational study
REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve Failure
Aortic Valve Stenosis
Not yet recruitingPhase 1/2
EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C)
Heterozygous Familial Hypercholesterolemia (HeFH)
RecruitingObservational study
Natural History of Noncirrhotic Portal Hypertension
Cystic Fibrosis, Immunologic Deficiency Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nengrui Guo principal investigator
Yuncheng First Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronary Heart Disease and Image, run by Nanjing University of Traditional Chinese Medicine at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 8 May 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Nengrui Guo (0086-17635599999, 657040251@qq.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change of brain volume before and after treatment (time frame: before operation; 3-10 Days after operation; 1 month; 6-12months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2023.